SWM
ABOS icon

Spire Wealth Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Spire Wealth Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,100
Closed -$21K – 2298
2022
Q3 		$21K Buy
+2,100
New +$12K ﹤0.01% 1304

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Spire Wealth Management's ABOS Position: Q4 2022 in Review

Spire Wealth Management sold out of Acumen Pharmaceuticals (ABOS) in Q4 2022, closing a stake of 2,100 shares — an estimated $21K sold.

Spire Wealth Management first reported a position in ABOS in Q3 2022 and held it in 1 quarter. The position peaked at $21K in Q3 2022. 60 funds tracked by Wall St. Rank hold ABOS as of Q4 2022.

  • Spire Wealth Management reported no remaining Acumen Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Spire Wealth Management sold 2,100 Acumen Pharmaceuticals shares in Q4 2022, an estimated $21K.
  • Spire Wealth Management first reported a position in Acumen Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Spire Wealth Management's Acumen Pharmaceuticals position peaked at $21K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2022.

Based on Spire Wealth Management's 13F filing for Q4 2022, filed 3 Feb 2023.